Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Secondary Hypogonadism
Interventions: Androxal (enclomiphene citrate), Testosterone; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Prostate, Cancer, Hormonal Cycling
Interventions: GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: THALASSEMIA MAJOR
Interventions: Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 12 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Eovist; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypogonadism, Atherosclerosis
Interventions: Testosterone Gel (Androgel), Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Male only
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts

Conditions: Sarcopenia, Muscle Weakness, Frailty
Interventions: Topical testosterone, Recombinant human growth hormone; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years to 90 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions: PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost; Diagnostic Test · Drug · Radiation
Lead sponsor: Martin T. King, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts

Conditions: Coronary Artery Disease
Interventions: AndroGel 5 Grams, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypogonadism
Interventions: Fispemifene once daily for 4 weeks; Drug
Lead sponsor: QuatRx Pharmaceuticals Company; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Huntsville, Alabama • Modesto, California • Aurora, Colorado + 13 more

Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 27
States / cities: Irvine, California • Los Angeles, California • Orange, California + 21 more

Conditions: Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions: Nestorone + Testosterone Combination Gel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Prostate Cancer
Interventions: Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide; Drug · Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 11
States / cities: Stamford, Connecticut • Boston, Massachusetts • Milford, Massachusetts + 6 more

Conditions: Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions: Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 326
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more

Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions: Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation; Device · Drug
Lead sponsor: Axial Therapeutic Research; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Northridge, California

Conditions: Hypogonadism, Male
Interventions: NatestoTM; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypoactive Sexual Desire Disorder
Interventions: transdermal testosterone gel 1%, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 66 Years · Female only
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 98
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: GTx-758; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more

Conditions: Hypogonadism, Male, Kidney Disease, Chronic
Interventions: Jatenzo Pill; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: LPCN 1144; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Roseville, California • Ocoee, Florida • Las Vegas, Nevada + 6 more

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more

Conditions: Aging, Frailty, Osteoporosis
Interventions: testosterone; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Rotator Cuff Tear
Interventions: Oxandrolone, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Reproductive Capacity and Iron Burden in Thalassemia

The COSMYC Trial (COmbined Suppression of MYC)

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Testosterone Replacement in Older Men and Atherosclerosis Progression

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Trifecta Research Study

Natesto Spermatogenesis Reboot

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

Testosterone Treatment in Men With Chronic Kidney Disease

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Testosterone Effects on Bone and Frailty

Oxandrolone Rotator Cuff Trial